دورية أكاديمية

Novel FOXF1-Stabilizing Compound TanFe Stimulates Lung Angiogenesis in Alveolar Capillary Dysplasia.

التفاصيل البيبلوغرافية
العنوان: Novel FOXF1-Stabilizing Compound TanFe Stimulates Lung Angiogenesis in Alveolar Capillary Dysplasia.
المؤلفون: Pradhan, Arun, Lixiao Che, Ustiyan, Vladimir, Reza, Abid A., Pek, Nicole M., Yufang Zhang, Alber, Andrea B., Kalin, Timothy R., Wambach, Jennifer A., Mingxia Gu, Kotton, Darrell N., Siefert, Matthew E., Ziady, Assem G., Kalin, Tanya V., Kalinichenko, Vladimir V.
المصدر: American Journal of Respiratory & Critical Care Medicine; 4/15/2023, Vol. 207 Issue 8, p1042-1054, 13p
مصطلحات موضوعية: INDUCED pluripotent stem cells, PULMONARY artery diseases, FORKHEAD transcription factors, NEOVASCULARIZATION, DYSPLASIA, VASCULAR cell adhesion molecule-1, PROTEOLYSIS
مستخلص: Rationale: Alveolar capillary dysplasia with misalignment of pulmonary veins (ACDMPV) is linked to heterozygous mutations in the FOXF1 (Forkhead Box F1) gene, a key transcriptional regulator of pulmonary vascular development. There are no effective treatments for ACDMPV other than lung transplant, and new pharmacological agents activating FOXF1 signaling are urgently needed. Objectives: Identify-small molecule compounds that stimulate FOXF1 signaling. Methods: We used mass spectrometry, immunoprecipitation, and the in vitro ubiquitination assay to identify TanFe (transcellular activator of nuclear FOXF1 expression), a smallmolecule compound from the nitrile group, which stabilizes the FOXF1 protein in the cell. The efficacy of TanFe was tested in mouse models of ACDMPV and acute lung injury and in human vascular organoids derived from induced pluripotent stem cells of a patient with ACDMPV. Measurements and Main Results: We identified HECTD1 as an E3 ubiquitin ligase involved in ubiquitination and degradation of the FOXF1 protein. The TanFe compound disrupted FOXF1-HECTD1 protein-protein interactions and decreased ubiquitination of the FOXF1 protein in pulmonary endothelial cells in vitro. TanFe increased protein concentrations of FOXF1 and its target genes Flk1, Flt1, and Cdh5 in LPS-injured mouse lungs, decreasing endothelial permeability and inhibiting lung inflammation. Treatment of pregnant mice with TanFe increased FOXF1 protein concentrations in lungs of Foxf11/2 embryos, stimulated neonatal lung angiogenesis, and completely prevented the mortality of Foxf11/2 mice after birth. TanFe increased angiogenesis in human vascular organoids derived from induced pluripotent stem cells of a patient with ACDMPV with FOXF1 deletion. Conclusions: TanFe is a novel activator of FOXF1, providing a new therapeutic candidate for treatment of ACDMPV and other neonatal pulmonary vascular diseases. [ABSTRACT FROM AUTHOR]
Copyright of American Journal of Respiratory & Critical Care Medicine is the property of American Thoracic Society and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:1073449X
DOI:10.1164/rccm.202207-1332OC